Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03096782 · ClinicalTrials.gov registry record · Phase 2
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03096782: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03096782 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03096782, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma. Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The umbilical cord blood cells will be grown ("expanded") on a special layer of cells collected from the bone marrow of healthy volunteers in a laboratory. A type of sugar will also be added to the cells in the laboratory that may help the transplant to "take" faster.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- BIOLOGICAL Anti-Thymocyte Globulin
- BIOLOGICAL Filgrastim-sndz
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03096782
The ClinicalTrials.gov registry entry for NCT03096782 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03096782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03096782 about?
NCT03096782 is a clinical study titled "Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma". This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma. Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth o...
What is the current status of trial NCT03096782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-10-13. Estimated completion is 2022-09-20.
What interventions are being tested in trial NCT03096782?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Anti-Thymocyte Globulin (BIOLOGICAL), Filgrastim-sndz (BIOLOGICAL), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT03096782?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.